Business
Parsortix potential for prostate cancer detection
Parsortix potential for prostate cancer detection.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 6690S Angle PLC 21 March 2016 \n\n\n\n\n\nFor immediate release\n\n\n 21 March 2016\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nBARTS PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR PROSTATE CANCER DETECTION CLINICAL APPLICATION\n \nPotential for a simple blood test to not only detect prostate cancer but also to assess the aggressiveness of the disease allowing risk stratification to active surveillance or intervention\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute's ongoing work with ANGLE's Parsortix system have provided evidence in support of the use of Parsortix in the detection and assessment of prostate cancer. \n \nBarts patient data suggests that the Parsortix system may be used both to detect prostate cancer and to assess its aggressiveness, all through a simple blood test. This is crucial because it means that men with low level disease could avoid unnecessary and potentially harmful solid biopsy and surgical intervention instead having \"active surveillance\", whereas men with an aggressive form of disease could be fast-tracked for further investigation and treatment. The current gold standard for detection is the prostate-specific antigen (PSA) blood test, which is known to have low sensitivity and low specificity (i.e. high levels of false positives) and the digital rectal exam (DRE - which is less effective than the PSA test). Where the PSA level is high or the DRE indicates an enlarged prostate, a solid prostate biopsy will be undertaken to detect cancer and assess the aggressiveness of the disease. This process results in many men having invasive biopsies unnecessarily. \n \nProstate cancer is the second most common cancer in men and the fourth most common overall. More than 1.1 million new cases of prostate cancer were recorded in 2012, accounting for around 8 per cent of all new cancer cases and 15 per cent in men with an estimated 3.9 million men living with the disease (Source: World Cancer Research Fund International) and as the risk increases with age and men are living longer these numbers are increasing. There is a far larger population of men with a variety of symptoms that require investigation for ...